pCDH-puro-myr-HA-Akt1 Citations (13)

Originally described in: Inhibition of BET bromodomain targets genetically diverse glioblastoma.
Cheng Z, Gong Y, Ma Y, Lu K, Lu X, Pierce LA, Thompson RC, Muller S, Knapp S, Wang J Clin Cancer Res. 2013 Apr 1;19(7):1748-59. doi: 10.1158/1078-0432.CCR-12-3066. Epub 2013 Feb 12. PubMed Journal

---

Articles Citing pCDH-puro-myr-HA-Akt1

Articles
Nuclear Localization of DNAJB6 Is Associated With Survival of Patients With Esophageal Cancer and Reduces AKT Signaling and Proliferation of Cancer Cells. Yu VZ, Wong VC, Dai W, Ko JM, Lam AK, Chan KW, Samant RS, Lung HL, Shuen WH, Law S, Chan YP, Lee NP, Tong DK, Law TT, Lee VH, Lung ML. Gastroenterology. 2015 Dec;149(7):1825-1836.e5. doi: 10.1053/j.gastro.2015.08.025. Epub 2015 Aug 22. PubMed
AS1411-Induced Growth Inhibition of Glioma Cells by Up-Regulation of p53 and Down-Regulation of Bcl-2 and Akt1 via Nucleolin. Cheng Y, Zhao G, Zhang S, Nigim F, Zhou G, Yu Z, Song Y, Chen Y, Li Y. PLoS One. 2016 Dec 1;11(12):e0167094. doi: 10.1371/journal.pone.0167094. eCollection 2016. PubMed
Loss of PFKFB4 induces cell death in mitotically arrested ovarian cancer cells. Taylor C, Mannion D, Miranda F, Karaminejadranjbar M, Herrero-Gonzalez S, Hellner K, Zheng Y, Bartholomeusz G, Bast RC Jr, Ahmed AA. Oncotarget. 2017 Mar 14;8(11):17960-17980. doi: 10.18632/oncotarget.14910. PubMed
FOXO Transcription Factors Both Suppress and Support Breast Cancer Progression. Hornsveld M, Smits LMM, Meerlo M, van Amersfoort M, Groot Koerkamp MJA, van Leenen D, Kloet DEA, Holstege FCP, Derksen PWB, Burgering BMT, Dansen TB. Cancer Res. 2018 May 1;78(9):2356-2369. doi: 10.1158/0008-5472.CAN-17-2511. Epub 2018 Feb 12. PubMed
Endoplasmic reticulum-localized ECM1b suppresses tumor growth and regulates MYC and MTORC1 through modulating MTORC2 activation in esophageal squamous cell carcinoma. Yu VZ, Ko JMY, Ning L, Dai W, Law S, Lung ML. Cancer Lett. 2019 Oct 1;461:56-64. doi: 10.1016/j.canlet.2019.07.005. Epub 2019 Jul 15. PubMed
LSD1 negatively regulates autophagy in myoblast cells by driving PTEN degradation. Shi YX, He YJ, Zhou Y, Li HK, Yang D, Li RY, Deng ZL, Gao YF. Biochem Biophys Res Commun. 2020 Feb 19;522(4):924-930. doi: 10.1016/j.bbrc.2019.11.182. Epub 2019 Dec 3. PubMed
RNF167 activates mTORC1 and promotes tumorigenesis by targeting CASTOR1 for ubiquitination and degradation. Li T, Wang X, Ju E, da Silva SR, Chen L, Zhang X, Wei S, Gao SJ. Nat Commun. 2021 Feb 16;12(1):1055. doi: 10.1038/s41467-021-21206-3. PubMed
Reprogramming an energetic AKT-PAK5 axis boosts axon energy supply and facilitates neuron survival and regeneration after injury and ischemia. Huang N, Li S, Xie Y, Han Q, Xu XM, Sheng ZH. Curr Biol. 2021 Jul 26;31(14):3098-3114.e7. doi: 10.1016/j.cub.2021.04.079. Epub 2021 Jun 3. PubMed
Intracellular Cholesterol Pools Regulate Oncogenic Signaling and Epigenetic Circuitries in Early T-cell Precursor Acute Lymphoblastic Leukemia. Rashkovan M, Albero R, Gianni F, Perez-Duran P, Miller HI, Mackey AL, Paietta EM, Tallman MS, Rowe JM, Litzow MR, Wiernik PH, Luger S, Sulis ML, Soni RK, Ferrando AA. Cancer Discov. 2022 Mar 1;12(3):856-871. doi: 10.1158/2159-8290.CD-21-0551. PubMed
Plantamajoside promotes metformin-induced apoptosis, autophagy and proliferation arrest of liver cancer cells via suppressing Akt/GSK3beta signaling. Wang Z, Zuo J, Zhang L, Zhang Z, Wei Y. Hum Exp Toxicol. 2022 Jan-Dec;41:9603271221078868. doi: 10.1177/09603271221078868. PubMed
Dual mTORC1/2 Inhibition Synergistically Enhances AML Cell Death in Combination with the BCL2 Antagonist Venetoclax. Satta T, Li L, Chalasani SL, Hu X, Nkwocha J, Sharma K, Kmieciak M, Rahmani M, Zhou L, Grant S. Clin Cancer Res. 2023 Apr 3;29(7):1332-1343. doi: 10.1158/1078-0432.CCR-22-2729. PubMed
Anticancer effect of involucrasin A on colorectal cancer cells by modulating the Akt/MDM2/p53 pathway. Wei C, Du J, Shen Y, Wang Z, Lin Q, Chen J, Zhang F, Lin W, Wang Z, Yang Z, Ma W. Oncol Lett. 2023 Apr 12;25(6):218. doi: 10.3892/ol.2023.13804. eCollection 2023 Jun. PubMed
Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors. Lv X, Lu X, Cao J, Luo Q, Ding Y, Peng F, Pataer A, Lu D, Han D, Malmberg E, Chan DW, Wang X, Savage SR, Mao S, Yu J, Peng F, Yan L, Meng H, Maneix L, Han Y, Chen Y, Yao W, Chang EC, Catic A, Lin X, Miles G, Huang P, Sun Z, Burt B, Wang H, Wang J, Yao QC, Zhang B, Roth JA, O'Malley BW, Ellis MJ, Rimawi MF, Ying H, Chen X. Science. 2023 Sep 8;381(6662):eabn4180. doi: 10.1126/science.abn4180. Epub 2023 Sep 8. PubMed

If you have published an article using this material, please email us at to have your article added to this page.